J&J Dapoxetine Market Opportunity: Up To 60% Of Men Interested, PPD Says
Johnson & Johnson's Phase III premature ejaculation therapy dapoxetine will likely have a substantial market opportunity beyond the probable labeled indications for the drug, PPD CEO Fred Eshelman said during an investor conference Feb. 5
You may also be interested in...
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011